Tests worth taking in the perimenopause window

What this cluster is, and is not

Read this as the page on the site where the answer is not a Solgar supplement. The question women in this window arrive with is not which capsule to take but which test to trust — and the honest answer carries a UK-specific headline. NICE NG23, updated in 2024, is explicit that follicle-stimulating hormone testing is not required to diagnose perimenopause in women over 45 with typical symptoms; the diagnosis is clinical. [1]

Three threads of the literature are mature enough to write about with confidence for a UK woman in this window: the staging-of-reproductive-aging consensus that explains why single-day cycle hormone readings underperform in perimenopause specifically; [2] [3] [6] [8] [9] [12]

What the research examines

The findings below sort the testing-and-tracking landscape into what the research supports, what carries signal in perimenopause specifically, and what is theatre. The cards beneath them are written against UK availability, regulatory status, the research base behind the measurement, and an honest framing of what the result tells you.

Research findings

1. NICE does not recommend FSH testing to diagnose perimenopause in women over 45 with typical symptoms.

   The 2024 update of NICE NG23 is explicit. In women aged 45 and over presenting with vasomotor symptoms and a change in cycle, the diagnosis is clinical and a serum follicle-stimulating hormone test adds no diagnostic information. The guideline reserves FSH for women 40–45 with atypical presentations and women under 40 where premature ovarian insufficiency is suspected. The headline editorial implication: a £89 at-home hormone panel sold as a perimenopause diagnostic is selling a test the UK clinical guideline does not ask for.

   Source: NICE NG23 · 2024 update · Clinical guideline, England & Wales

2. Single-day cycle hormone readings carry limited information across the menopausal transition.

   The 2012 STRAW + 10 consensus describes the staging of reproductive aging across the menopausal transition and documents the dramatic cycle-to-cycle and within-cycle variability of oestradiol, progesterone and FSH that characterises the late reproductive stage and the early menopausal transition. A single venous draw on day 3 of a cycle does not place a woman on the staging system; the staging system is built from menstrual-bleeding criteria, with hormone markers as supportive context. This is the mechanistic reason at-home single-day hormone panels read as theatre in this window.

   Source: J Clin Endocrinol Metab · 2012 · Harlow et al. · International consensus, STRAW + 10

3. Continuous glucose monitor readings in normoglycemic adults show wide individual variability that does not map cleanly onto clinical risk.

   The Hall 2018 PLOS Biology study placed CGMs on adults the standard tests classified as normoglycemic and found post-meal glucose excursions reaching the prediabetic range 15% of the time and the diabetic range 2% of the time — variability that on a consumer-facing app reads as alarm, but that the international consensus on time-in-range targets does not flag as clinically actionable. The Berry 2020 PREDICT 1 trial in 1,002 UK adults reported a 68% population coefficient of variation in postprandial glucose responses to identical meals, driven more by individual factors than by macronutrient content. The CGM-in-non-diabetics question is alive in the research; the CGM as standalone health metric for women without diabetes is not where the evidence has landed.

   Source: PLOS Biol 2018 · Nat Med 2020 · Hall n=57; Berry n=1,002

4. Wearable temperature-and-physiology tracking detects ovulation more accurately than calendar methods, with caveats in irregular cycles.

   The Thigpen 2025 validation analysis on 1,155 ovulatory cycles from 964 Oura Ring users compared the device’s physiology-based ovulation date against ovulation predictor kits and against the calendar method. The physiology method detected 96.4% of ovulations with an average error of 1.26 days, against 3.44 days for the calendar method. Accuracy held across cycle lengths and across age 18–52, with reduced detection in short cycles. The clinical translation for a perimenopausal reader: the cycle-tracking signal a wearable provides is real, but is most informative for women still cycling; for women in late perimenopause with widely-spaced cycles, the tracking value declines because the cycles themselves do.

   Source: J Med Internet Res · 2025 · Thigpen et al. · Validation, n = 1,155 cycles, 964 users

Evidence at a glance

Reader questions

If NICE doesn’t recommend FSH testing, why are at-home hormone panels everywhere?

Because the test is cheap to run and the question is emotionally pressing. A £89 finger-prick panel that names oestradiol, progesterone and FSH carries the surface promise of an answer; the NICE NG23 guideline says the answer those three numbers give, on a single day in the menopausal transition, is not diagnostically useful for women over 45. The exception cases the guideline carves out — women 40–45 with atypical presentations, women under 40 where premature ovarian insufficiency is the question — are real, and a hormone panel ordered alongside a GP consultation has a place there. The case the guideline does not support is the routine direct-to-consumer panel as a perimenopause diagnostic.

Are CGMs useful for women without diabetes?

The honest reading of the literature: there is signal, and there is also a measurement-without-meaning problem. The Berry 2020 PREDICT 1 trial established that postprandial glucose responses to identical meals vary widely across UK adults, with person-specific factors carrying more weight than meal macronutrients for some markers. The Hall 2018 study showed adults considered normoglycemic by standard testing routinely show CGM excursions a consumer-facing app reads as red. The Bermingham 2022 ZOE PREDICT sub-analysis specifically reported less favourable post-meal glucose responses in post-menopausal versus pre-menopausal women in the same cohort — so the menopause-and-glucose question is real. The case for a CGM as a paid wellness device for a woman without diabetes is weaker than the marketing suggests; the case for a CGM as a research tool inside a programme like ZOE that pairs the data with nutritional context is stronger.

What about the Oura ring or an Apple Watch — is the cycle-tracking actually accurate?

The Thigpen 2025 validation analysis on 1,155 cycles found the Oura physiology-based ovulation date detected 96.4% of ovulations with a mean error of 1.26 days, against 3.44 days for the calendar method — meaningfully more accurate than calendar tracking, and stable across age 18–52. The caveat for a perimenopausal reader: the value of cycle tracking declines as cycles become more variable and widely spaced through the menopausal transition. The Cunningham 2024 Flo cohort of 19 million users documents the age-related drift — cycles get shorter and more variable through the late reproductive stage and then longer and more variable through the menopausal transition. A wearable tracks what is there to track; in late perimenopause, what is there to track is less.

What about menopause symptom tracker apps like Balance?

Symptom tracker apps are not diagnostic devices and are not regulated as such. What they are useful for is the same thing a paper diary would be useful for: a longitudinal record of which symptoms cluster, which days they cluster on, and what a GP consultation might benefit from being shown. The Balance app from Newson Health is the most-cited UK option, free at the point of use, and the research-context paper on its underlying data is the Bermingham 2022 ZOE PREDICT collaboration. The honest framing: a symptom tracker is a record-keeping tool to bring to a clinical conversation, not a substitute for one.

Why is this cluster a service review rather than a recommendation of a specific product line?

Because this is the page on the site where the answer is not a Solgar supplement. There is no supplement that diagnoses a hormone level, measures a glucose excursion, detects an ovulation date or logs a symptom — those are the jobs of tests, devices, wearables and apps. HerStack is published by Suggestic, a digital nutrition company; we picked Solgar UK as the reference brand for the supplement clusters where formulation matters. On this cluster, the criteria that matter are different — UK availability, regulatory status, the research base behind the measurement, and an honest framing of what the result tells you. The cards below are written against those criteria.

How often is this article updated?

We review each cluster page against new evidence quarterly, and update the page header date when we make a substantive change. The service/device cards below carry their own last-reviewed date so you can see when the provider price ranges and the regulatory status were last checked.

What we recommend: three services or tools, with editorial rationale

Each entry carries the category, the service or tool, the rationale, who it suits, the limit of what it tells you, the price range, and the provider URL. These are editorial outbound links, not affiliate links.

1. Forth Edge Female Hormone Mapping

   Category: At-home hormone testing · UK provider

   Rationale: Forth (Forth With Life Ltd, UK-registered, ISO 15189-accredited partner labs) operates the cleanest scientific framing in the UK at-home hormone-test category. The female-hormone panels measure oestradiol, FSH, LH, progesterone and testosterone from a finger-prick draw, with results contextualised against the cycle phase the user reports. Carded here as the reference UK provider in the category, with a heavy compliance caveat below — under NICE NG23 a hormone panel is not the diagnostic for perimenopause in women over 45.

   Suits: Suits: women 40–45 with atypical presentations, women under 45 where premature ovarian insufficiency is on the differential, and readers ordering tests in collaboration with a GP or private menopause clinic. Not the right starting point for a woman over 45 with vasomotor symptoms and a changing cycle, where the NICE NG23 reading is that the diagnosis is clinical.

   Caveat: What the test cannot tell you: where you sit on the STRAW + 10 staging system. Cycle hormones fluctuate dramatically through the menopausal transition; a single-day reading is a single point in a moving series, not a verdict.

   Price: From £89 single panel; subscription pricing varies

   Provider: https://www.forthwithlife.co.uk/

2. ZOE Health Programme (CGM + nutrition science)

   Category: Continuous glucose monitor · UK programme

   Rationale: ZOE (UK-headquartered, King’s College London research partnership) pairs a two-week CGM wear, a gut-microbiome sample and a postprandial blood-fat test with personalised food scores derived from the PREDICT trial database. Carded here on the strength of the research base: the Berry 2020 PREDICT 1 trial in Nature Medicine (n = 1,002 UK adults), the Asnicar 2021 microbiome paper in Nature Medicine, and the Bermingham 2022 menopause sub-analysis in EBioMedicine that specifically documents post-meal metabolic differences across the menopausal transition.

   Suits: Suits: women in the menopausal transition who want their nutritional pattern read against their own postprandial responses rather than generic guidance, and who are willing to engage with the programme rather than treat the CGM as a standalone wellness device. Less suitable for readers who want a CGM alone — the research base behind ZOE is the pairing of the device with the nutritional context, not the device on its own.

   Caveat: What a CGM does not tell you: whether the variability you see is clinically meaningful. The Hall 2018 glucotypes paper documents wide post-meal swings in adults the standard tests classify as normoglycemic; the international consensus on time-in-range targets is written for people with diabetes, not for healthy adults. Read the readings as research-context, not as a diagnosis.

   Price: From £299 setup; £24.99/month membership

   Provider: https://zoe.com/

3. Balance Menopause Support (Newson Health)

   Category: Menopause symptom tracker · UK app

   Rationale: The Balance app (Newson Health, UK) is the most-used menopause-specific symptom tracker in the UK and is free at the point of use. It logs symptoms, generates a Health Report a reader can take to a GP consultation, and links to evidence summaries from the Newson Health team. Carded here on availability, cost and clinical-conversation utility grounds — not on benefit-claim grounds.

   Suits: Suits: readers approaching a GP consultation who want a longitudinal symptom record rather than a recall of the past two weeks, and readers tracking the response to interventions across cycles. The free pricing means the cost-benefit calculus is friendly even where the personal utility turns out to be modest.

   Caveat: What an app does not do: diagnose a clinical condition or substitute for a clinician’s review. A symptom tracker is a record-keeping tool, not a regulated medical device. The Cunningham 2024 Flo cohort paper documents the population-level patterns symptom-tracker data captures; individual readings are still individual readings.

   Price: Free (in-app upgrades available)

   Provider: https://balance-menopause.com/

What to look for in a test or service: three criteria

1. Honest framing of what the result tells you. A result is only as useful as the question it answers. An at-home FSH reading on day 3 of a perimenopausal cycle does not tell you where you sit on the STRAW + 10 staging system; a CGM reading on a healthy adult does not map onto the time-in-range consensus written for people with diabetes. Services that frame the result honestly — including its limits — operate inside the research; services that frame the result as a diagnosis operate outside it.
2. UK regulatory status and accreditation. At-home medical tests in the UK fall under the Medicines and Healthcare products Regulatory Agency framework. Look for ISO 15189-accredited labs (the standard for medical-laboratory quality), a registered UK address for the provider, and ASA / CAP-compliant marketing copy. Tests that flag clinical conditions through unaccredited labs, or that lean on freer benefit language than UK rules permit, are operating outside the regulatory framework.
3. The research base behind the measurement. A device or service is worth its price when the measurement it returns has a published research base — validation papers, peer-reviewed cohort work, and a literature trail you can read. The Oura ovulation validation, the ZOE PREDICT trial series, and the Flo Health cycle-cohort paper all carry that trail. A product that markets a benefit without a published research base behind the underlying measurement is asking you to trust the marketing.

Citations

1. [1] National Institute for Health and Care Excellence. Menopause: identification and management (NG23). NICE guideline, published November 2015, updated November 2024. nice.org.uk/guidance/ng23
2. [2] Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 2012;97(4):1159-1168. PMID 22344196
3. [3] Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. Nature Medicine, 2020;26(6):964-973. (PREDICT 1 trial, UK n = 1,002.) PMID 32528151
4. [4] Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nature Medicine, 2021;27(2):321-332. PMID 33432175
5. [5] Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, et al. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine, 2022;85:104303. (UK cohort, n = 1,002; pre-, peri- and post-menopausal.) PMID 36270905
6. [6] Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLOS Biology, 2018;16(7):e2005143. PMID 30040822
7. [7] Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019;42(8):1593-1603. PMID 31177185
8. [8] Thigpen N, Patel S, Zhang X. Oura Ring as a tool for ovulation detection: validation analysis. Journal of Medical Internet Research, 2025;27:e60667. (Validation, 1,155 cycles in 964 users.) PMID 39889300
9. [9] Cunningham AC, Pal L, Wickham AP, Prentice C, Goddard FGB, Klepchukova A, Zhaunova L. Chronicling menstrual cycle patterns across the reproductive lifespan with real-world data. Scientific Reports, 2024;14:10172. (Flo Health UK, n > 19 million users aged 18–55.) PMID 38702411
10. [10] Medicines and Healthcare products Regulatory Agency. In vitro diagnostic medical devices: guidance on legislation (UK Medical Devices Regulations 2002, as amended). MHRA, retained 2024. gov.uk/mhra-ivd-guidance
11. [11] NHS England. Menopause — diagnosis, symptoms and treatment pathways. NHS, retained 2025. nhs.uk/conditions/menopause
12. [12] British Menopause Society. Tools for clinicians: 2024 update — including guidance on investigation, diagnosis and treatment of women in the menopausal transition. BMS, 2024. thebms.org.uk/tools-for-clinicians
13. [13] Advertising Standards Authority / Committee of Advertising Practice. Health: at-home medical tests, and Health: medical devices — rulings and guidance on UK marketing of direct-to-consumer diagnostic and monitoring products. ASA / CAP, retained 2025. asa.org.uk/advice-and-resources
14. [14] Royal College of Obstetricians and Gynaecologists. Menopause and women’s health in later life — RCOG position statements and patient information. RCOG, retained 2024. rcog.org.uk/menopause